Prescriber Scope of Practice for Weight Loss/GLP-1 in Michigan

If you’re a psychiatrist or PMHNP considering adding weight management to your practice — or already fielding patient requests for GLP-1s like Ozempic — you’re not alone. The explosion in demand for weight-loss medications has every prescriber asking the same questions: Can I legally do this via telehealth? What about controlled substances like phentermine? Will my state medical board consider this ‘out of scope’?

Here’s the reality: Yes, psychiatrists can prescribe weight-loss medications, including via telehealth — but the rules vary wildly by state, and the difference between doing this legally versus stepping into a regulatory minefield comes down to understanding three things: federal DEA rules, your state’s telehealth prescribing laws, and whether you’re treating obesity as a physician (full authority) or as a psychiatric NP (potentially outside your scope without oversight).

Let’s cut through the confusion with what you actually need to know to practice safely and profitably.

The Federal Landscape: DEA Rules Through 2026 (and What Comes Next)

The short version: You can prescribe controlled weight-loss medications (like phentermine) via telehealth through December 31, 2026 without an in-person visit — but this is temporary, and permanent rules are coming.

Before COVID, federal law (the Ryan Haight Act) required an in-person medical exam before prescribing any controlled substance via telemedicine. That was waived during the pandemic. In January 2026, the DEA and HHS extended those flexibilities again — specifically to prevent a ‘telehealth cliff’ where millions of patients would suddenly lose access to ADHD medications, anxiety meds, and yes, weight-loss drugs like phentermine.

What this means for you:

• Through 2026: You can prescribe Schedule III-V controlled substances (phentermine is Schedule IV) to new patients via video visit, no in-person exam required federally
• GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound) are not controlled substances — no DEA restrictions at all, can prescribe via telehealth indefinitely under standard prescribing rules
• After 2026: The DEA is drafting permanent rules that will likely require either a ‘special telemedicine registration’ or initial supply limits (e.g., 30-day max for first prescription). They’re also considering restricting Schedule II stimulants to same-state prescribing only.

The business impact: If you’re building a telehealth weight-loss practice around phentermine, plan for regulatory changes in 2027. GLP-1-based practices have more regulatory runway.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Rules: Where Things Get Complicated

Federal law sets the floor. States can be stricter — and many are. Here’s where psychiatrists run into problems: assuming that because the DEA allows something, their state does too.

The States That Said ‘Not So Fast’

New York essentially ignored the federal waiver. As of May 2025, New York requires an in-person medical evaluation before prescribing any controlled substance via telehealth — with narrow exceptions (another provider saw the patient in the past 12 months and shared records, you’re covering for a colleague, or it’s a 5-day emergency supply for an existing patient).

Translation: If you’re NY-licensed and want to start a new patient on phentermine via telehealth, you legally can’t — unless you see them in person first or coordinate with another provider who did. GLP-1s? No problem, since they’re not controlled.

Florida took a different approach: they allow telehealth prescribing of Schedule III-V drugs (phentermine is fine), but they ban teleprescribing Schedule II stimulants unless it’s for psychiatric treatment, inpatient care, hospice, or nursing home patients. So a Florida psychiatrist can prescribe Adderall via video for ADHD (psychiatric exception), but if you tried to prescribe it off-label for obesity, you’d be breaking state law.

The States That Are Telehealth-Friendly (With Strings Attached)

California, Texas, Pennsylvania, Illinois — all permit telehealth prescribing of controlled substances under the current DEA extension, with no state-level in-person requirement.

But — and this is critical — they have their own compliance hoops:

California:

• Must check the CURES PDMP database before first prescription of any Schedule II-IV drug, then every 4 months for ongoing therapy
• Requires documented patient consent for telehealth (can be electronic, but must be on file)
• Corporate Practice of Medicine doctrine means you can’t just partner with a non-physician business — the practice must be physician-owned or structured through a compliant MSO

Texas:

• Must establish a valid patient relationship via live video (or store-and-forward with audio if it meets standard of care — practically, use video)
• Required to check the Texas PMP before prescribing certain controlled substances (mandated for opioids/benzos/barbs; best practice for all)
• Must send a care summary to the patient’s primary care provider within 72 hours (with patient consent)
• NPs and PAs cannot prescribe independently — need a Prescriptive Authority Agreement with a Texas MD/DO that explicitly covers weight-loss medications

Florida:

• Beyond the Schedule II restriction, Florida has the most prescriptive obesity-treatment rules in the country:
• Patient must have BMI ≥30 (or ≥27 with comorbidities) — document this
• Must obtain written informed consent outlining risks of weight-loss drugs
• Must re-evaluate patients every 3 months minimum if on anti-obesity medications
• Must provide each patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’
• Cannot prescribe SSRIs off-label for weight loss (explicitly prohibited by state rule)
• Must check E-FORCSE PDMP before prescribing any controlled substance to patients ≥16 years old

Pennsylvania & Illinois:

• PA: No specific telehealth statute; follows federal law. Must check PA PDMP before prescribing opioids/benzos (recommended for all controlled substances). NPs need collaborative agreements.
• IL: Very telehealth-friendly. NPs can achieve Full Practice Authority after 4,000 hours, allowing independent prescribing including controlled substances. Must check IL PMP for Schedule II narcotics.

Psychiatrist vs PMHNP: Scope of Practice Realities

Here’s where the ‘can I do this?’ question gets personal.

For Psychiatrists (MD/DO):

Legal answer: Yes. You have an unrestricted medical license. You can prescribe weight-loss medications — GLP-1s, phentermine, whatever is FDA-approved or used off-label within standard of care.

Practical answer: You should only if you’re competent to do so. State medical boards will hold you to the same standard of care as an obesity medicine specialist or internist treating weight management. That means:

• Documenting a comprehensive evaluation (BMI, comorbidities, contraindications)
• Ruling out secondary causes of obesity (thyroid, Cushing’s, medications)
• Counseling on diet, exercise, behavioral modification (or referring to someone who can)
• Monitoring for side effects and efficacy
• Following state-specific rules (like Florida’s quarterly follow-ups)

Some psychiatrists are pursuing Board Certification in Obesity Medicine through the American Board of Obesity Medicine to strengthen their credentials — not required, but helps if you’re marketing this as a service.

The business case: Many of your patients already struggle with weight gain from antipsychotics or mood stabilizers. Adding GLP-1s to your practice can be a natural extension — you’re already managing their medications and can address weight as a comorbidity. The key is doing it thoroughly, not as an add-on afterthought.

For PMHNPs:

Legal answer: Maybe. It depends on your state’s scope-of-practice laws and whether you have physician oversight.

Your PMHNP certification is in psychiatric-mental health. Treating obesity is traditionally primary care or endocrinology. Some state nursing boards would consider prescribing purely for weight loss to be outside your training and scope — which could trigger disciplinary action if a complaint is filed.

How PMHNPs are doing this legally:

1. Collaboration with a physician (family medicine, internal medicine, or obesity specialist) who provides oversight and protocols. In states like Texas and Florida, this is essentially required.
2. Independent practice in states that allow it (California post-2026, Illinois with FPA) — but even then, you’re expected to practice within your competence. If you market yourself as a weight-loss specialist without additional training, boards could question it.
3. Additional certification or training — some NPs pursue obesity medicine courses or certificates to demonstrate competency.

State-specific:

• California: NPs can achieve independent practice under AB 890 (as of 2026 for experienced NPs), but obesity treatment would still be scrutinized as potentially outside psych-NP scope unless you have documented training
• Texas: NPs must have a PAA (Prescriptive Authority Agreement) with a physician; that physician should ideally have expertise in the area you’re prescribing for (so a psychiatrist supervising a psych NP for obesity treatment might not satisfy regulatory expectations — get an internist involved)
• Florida: Psych NPs still require physician collaboration (autonomous practice bills for psych NPs haven’t passed as of 2025). You’d need a collaborating physician and should stick to mental health unless explicitly delegated other duties.

The business reality: If you’re a PMHNP and want to add weight management, structure it as part of integrated care (treating depression + obesity, for example) and bring in physician oversight. Don’t go solo on this unless your state explicitly allows it and you have the training to back it up.

The Economics: Why Platforms Beat DIY Marketing (Reality Check)

You’re probably thinking: ‘Okay, I can do this legally — but how do I actually get patients?’

Let’s talk numbers, because this is where most providers get burned.

The myth: ‘I’ll just run some Google Ads and list on Psychology Today for $30/month. Patients will find me.’

The reality: Acquiring a qualified psychiatric or weight-loss patient through DIY marketing costs $200-500+ per booked patient when you factor in:

• Google Ads for ‘weight loss doctor near me’ or ‘GLP-1 prescription online’ run $15-40+ per click
• Most clicks don’t convert (maybe 2-5% book an appointment)
• You need to test campaigns for months, burning through budget
• Agency fees if you hire help ($2,000-5,000/month for a decent agency)
• Staff time handling inquiries, qualifying leads, dealing with no-shows from cold leads
• SEO takes 6-12 months of consistent investment ($1,500-3,000/month) before you see meaningful traffic

Psychology Today, Zocdoc, directory listings: These charge monthly fees ($30-100+), but you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100 per lead), and total monthly costs add up fast when you factor in subscription + per-booking fees.

Do the math: If you spend $3,000/month on marketing and acquire 10 new patients, that’s $300 per patient — and that’s if your campaigns are optimized. Most solo providers spend 3-6 months in the red before they dial in what works.

Why Platforms Like Klarity Make Economic Sense

Klarity uses a pay-per-appointment model similar to Zocdoc, but with a critical difference: you only pay when a pre-qualified patient books with you. No upfront marketing spend. No monthly subscriptions gambling on SEO. No wasted ad budget on clicks that ghost you.

Value props:

• Pre-qualified patients already matched to your specialty, availability, and patient type (insurance vs cash-pay)
• Built-in telehealth infrastructure — no separate platform costs ($50-200/month saved)
• Both insurance and cash-pay patient flow — you choose your payer mix
• You control your schedule — take as many or as few patients as you want; you only pay the listing fee when someone books

The real comparison:

• DIY marketing: $3,000-5,000/month with uncertain results, 3-6 month ramp-up, ongoing time managing campaigns
• Klarity: Standard listing fee per new patient lead, guaranteed ROI (you only pay when you see patients), zero marketing effort on your end

For psychiatrists starting out or scaling an existing practice, platforms remove the patient acquisition gamble entirely. You’re trading a small per-patient fee for predictable patient flow without burning through cash on marketing experiments.

State-Specific Deep Dives: What You Actually Need to Do

California

Bottom line: GLP-1s are straightforward via telehealth. Phentermine requires CURES check first, then every 4 months. Get documented telehealth consent. If you’re an NP, you need standardized procedures with a physician (or independent practice credentials as of 2026).

Local tip: Medi-Cal stops covering GLP-1s for weight loss in January 2026 — expect a surge in cash-pay telehealth demand. Position yourself for self-pay patients.

Texas

Bottom line: Live video exam is fine for prescribing. Must send care summary to patient’s PCP within 72 hours. NPs/PAs need a PAA covering weight-loss meds. Check Tx PMP for controlled substances (phentermine).

Local tip: High obesity rates = strong demand. Rural areas underserved — telehealth opportunity. Watch for TMB enforcement on misleading weight-loss advertising.

Florida

Bottom line: Most prescriptive state rules. Document BMI, get written consent, quarterly follow-ups minimum, provide Consumer Bill of Rights. Cannot teleprescribe Schedule II except for psych treatment. Check E-FORCSE before any controlled Rx.

Local tip: High competition from established weight-loss clinics. Regulators are vigilant (pill mill history). Follow the rules to the letter — quarterly video visits, proper documentation, informed consent on file.

New York

Bottom line: Cannot prescribe controlled substances (phentermine) via telehealth to new patients without in-person exam (unless exceptions apply). GLP-1s are fine. Must check NY PMP within 24 hours before any Schedule II-IV prescription. E-prescribing mandatory.

Local tip: High demand in NYC for GLP-1s. If you want to prescribe phentermine, partner with a clinic for in-person initial visits or coordinate with another provider’s exam. Hybrid models (virtual + occasional in-person) work.

Pennsylvania

Bottom line: No state telehealth statute; follows federal law. Check PA PDMP before opioid/benzo scripts (recommended for all controlled substances). NPs need collaborative agreements.

Local tip: Large rural population underserved for specialty care. Telehealth fills a gap. Conservative regulatory environment — document thoroughly, practice to high standard.

Illinois

Bottom line: Telehealth-friendly. NPs can achieve Full Practice Authority (independent prescribing after 4,000 hours). Check IL PMP for Schedule II narcotics. No in-person requirement.

Local tip: Supportive state policies. Chicago market competitive; rural southern IL underserved. Illinois Medicaid covers weight-loss drugs (unlike California) — insurance billing opportunity.

Compliance Checklist: How to Stay Out of Trouble

Whether you’re prescribing GLP-1s or phentermine, here’s your regulatory survival guide:

✅ Verify patient location every visit — you must be licensed in the state where the patient is located, not where you are

✅ Obtain and document telehealth consent (required in CA, IL, others; best practice everywhere)

✅ Conduct and document a thorough evaluation:

• History (weight history, prior attempts, comorbidities)
• Current medications (drug interactions?)
• Contraindications (pregnancy, heart disease for phentermine)
• BMI calculation (document the number)
• Mental health screening (especially if you’re a psychiatrist — address any eating disorders, depression)
• Diet/exercise counseling (or refer to RD/nutritionist)

✅ Follow state-specific rules:

• Florida: Written informed consent, quarterly follow-ups, Consumer Bill of Rights
• New York: In-person exam for controlled substances, PMP check within 24 hours
• California: CURES query first and every 4 months, telehealth consent
• Texas: PMP check, care summary to PCP within 72 hours

✅ Use PDMPs diligently:

• Check before prescribing controlled substances (state mandates vary, but best practice for all)
• Document in your note: ‘Checked [State] PMP on [date], no concerning findings’ or ‘Patient has active benzodiazepine prescription from Dr. X — discussed interaction risk’

✅ E-prescribe:

• Many states (CA, NY, IL, FL) require electronic prescribing for controlled substances
• Use a certified EPCS system

✅ Schedule follow-ups:

• GLP-1s: monthly for dose titration, then every 3 months per most guidelines
• Phentermine: every 3 months minimum (Florida requires this; good practice everywhere)
• Document weight, blood pressure, side effects, patient goals/progress each visit

✅ Coordinate care:

• Inform patient’s PCP (with consent) — especially important for psychiatrists treating a condition outside primary specialty
• Refer as appropriate (RD for meal planning, endocrinology if complex metabolic issues)

The Bottom Line: Can You Do This Profitably and Legally?

Yes — if you approach it like a real clinical service, not a side hustle.

Psychiatrists have the legal authority to prescribe weight-loss medications. The question is whether you have the competence, infrastructure, and compliance systems to do it safely and sustainably.

For psychiatrists: Adding weight management (especially GLP-1s for patients with medication-induced weight gain) can be a natural extension of your practice. But don’t half-ass it. Get the training, follow the protocols, document everything. Consider obesity medicine certification if you’re serious about this as a revenue stream.

For PMHNPs: You’ll need physician oversight in most states. Don’t try to go solo unless your state explicitly allows it and you have documented competency. Team up with a family medicine doc or endocrinologist who can provide supervision and credibility.

For everyone: The economics of patient acquisition are brutal if you go the DIY route. Platforms like Klarity remove the marketing gamble — you get pre-qualified patients, built-in telehealth infrastructure, and you only pay when patients book. That’s predictable ROI vs. months of burning cash on ads and SEO.

State rules vary wildly. New York requires in-person visits for controlled substances. Florida has the most prescriptive obesity rules. California is GLP-1-friendly but strict on corporate practice. Know your state’s laws and follow them to the letter.

Ready to Add Weight Management to Your Practice (the Right Way)?

If you’re licensed in a telehealth-friendly state and want to see qualified weight-loss patients without the marketing headache, Klarity Health’s provider network is worth exploring. We match you with patients already looking for your expertise, handle the infrastructure, and you control your schedule — pay only when patients book.

Explore Klarity’s Provider Platform →

FAQ: Weight-Loss Prescribing for Psychiatrists

Can psychiatrists prescribe GLP-1 medications like Ozempic or Wegovy via telehealth?

Yes. GLP-1 agonists (semaglutide, tirzepatide) are not controlled substances, so they aren’t subject to DEA telehealth restrictions. As long as you conduct an appropriate telehealth evaluation that meets your state’s standard of care, you can prescribe them. Most states allow video visits to establish a patient relationship; some require documented informed consent for telehealth.

Can I prescribe phentermine (a controlled substance) via telehealth?

It depends on your state. Federally, the DEA allows telehealth prescribing of Schedule IV controlled substances (phentermine) through December 31, 2026, without an in-person visit. However, New York requires an in-person exam before prescribing any controlled substance via telehealth (with narrow exceptions). Florida, Texas, California, Pennsylvania, and Illinois permit telehealth prescribing of phentermine under current federal allowances, but each has state-specific compliance requirements (PDMP checks, documentation, follow-ups). Always verify your state’s rules.

Do I need special certification to prescribe weight-loss medications as a psychiatrist?

No legal requirement, but it strengthens your credibility and competency. The American Board of Obesity Medicine offers board certification in obesity medicine (open to all physicians). Many psychiatrists pursue this if they’re adding weight management as a formal service line. At minimum, you should be familiar with obesity treatment guidelines, contraindications, and monitoring protocols to meet the standard of care.

Can a PMHNP prescribe weight-loss drugs independently?

Generally no, unless your state allows independent practice and you have documented training in obesity treatment. Most state nursing boards expect NPs to practice within their scope (mental health for PMHNPs). Prescribing for obesity may be viewed as outside that scope unless done under physician supervision or with additional certification. In Texas and Florida, NPs need physician oversight. In California (post-2026) and Illinois (with FPA), experienced NPs can practice independently, but treating obesity would still require demonstrating competence in that area.

What are the biggest compliance risks when prescribing weight-loss drugs via telehealth?

1. Prescribing controlled substances in states that require in-person exams (e.g., New York) — this violates state law.
2. Failing to check state PDMP databases before prescribing controlled substances (required in most states; failure to check can result in disciplinary action).
3. Inadequate documentation — state medical boards expect the same thoroughness as in-person care (history, exam findings, informed consent, follow-up plan).
4. Not following state-specific obesity prescribing rules (e.g., Florida’s quarterly re-evaluations, written consent) — violating these can trigger complaints.
5. Practicing outside your scope (especially for NPs/PAs) — state boards will investigate if they believe you’re treating conditions beyond your training without appropriate oversight.

How much does it cost to acquire weight-loss patients through traditional marketing vs. a platform like Klarity?

DIY marketing: Expect $200-500+ per booked patient when you factor in Google Ads ($15-40/click, low conversion rates), SEO investment ($1,500-3,000/month for 6-12 months before results), agency fees ($2,000-5,000/month), and staff time handling leads. Most solo providers spend 3-6 months in the red before campaigns are profitable.

Klarity platform: Pay-per-appointment model — you only pay a standard listing fee when a pre-qualified patient books with you. No upfront marketing spend, no monthly subscriptions, no wasted ad budget. You get matched patients, built-in telehealth infrastructure, and control over your schedule. This removes patient acquisition risk entirely — guaranteed ROI vs. gambling on marketing channels.

Citations & References

1. U.S. Department of Health & Human Services (January 2, 2026). HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026. [Press Release]. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Florida Statutes § 456.47 (2019, accessed November 2025). Use of Telehealth to Provide Services (Florida Telehealth Act). http://www.leg.state.fl.us/statutes/

3. Florida Administrative Code 64B8-9.012 (Effective August 8, 2022). Standards for the Prescription of Drugs to Treat Obesity. https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

4. Goodwin Procter LLP (March 30, 2024). A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs. [Client Alert]. https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

5. McDermott Will & Emery LLP (September 29, 2023). Weight-Loss Programs in Florida: State Law Considerations for GLP-1 Telehealth Providers. https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

6. Medical Director Compliance Consulting (2025). California Weight Loss Clinic & Telehealth Compliance Guide (2025). https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

7. Medical Director Compliance Consulting (2025). Texas Weight Loss Clinic & Telehealth Compliance Guide (2025). https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

8. New York State Department of Health, 10 NYCRR §80.63 (Amended May 2025). Prescribing of Controlled Substances. https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

9. Fierce Healthcare / Heather Landi (February 13, 2025). Primary care doctors concerned about telehealth GLP-1 boom: survey. https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

10. California Medical Association (December 2, 2025). GLP-1 medications for weight loss will no longer be covered by Medi-Cal. https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

11. Center for Connected Health Policy (Updated November 21, 2025). State Telehealth Policies: Online Prescribing. https://www.cchpca.org/topic/online-prescribing/

12. Pennsylvania Department of Health (2022, accessed 2025). Prescription Drug Monitoring Program – Prescriber FAQs. https://www.pa.gov/agencies/health/programs/opioids/prescribers-and-providers/prescribing-guidelines.html

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated